Imatinib Stada Arzneimittel

Imatinib, the active ingredient in Imatinib Stada Arzneimittel, is a tyrosine kinase inhibitor presented as a tablet for oral use. It is indicated for the treatment of chronic myeloid leukemia and gastrointestinal stromal tumor in adult patients and is administered under medical supervision.

GNH USA supplies Imatinib Stada Arzneimittel as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for each shipment. Customers benefit from reliable lead times and comprehensive after‑sales support.

Imatinib targets BCR‑ABL‑positive leukemic cells and tumors driven by c‑KIT or PDGFR signaling.

Chronic Myeloid Leukemia (CML): reduces malignant clone proliferation and induces cytogenetic remission. Gastrointestinal Stromal Tumor (GIST): inhibits tumor growth and can achieve disease control in patients with KIT or PDGFRA mutations.

Imatinib is associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Edema: peripheral swelling, especially around ankles. - Fatigue: persistent tiredness affecting daily activities. - Diarrhea: loose stools, often self‑limiting.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or hepatitis. - Severe neutropenia: marked reduction in white blood cells increasing infection risk. - Cardiac failure: reduced left‑ventricular ejection fraction or congestive symptoms. - Pulmonary hypertension: elevated pulmonary arterial pressure leading to dyspnea.

Before initiating therapy, clinicians should evaluate several clinical parameters and counsel patients on safety measures. - Baseline blood counts: monitor leukocytes, neutrophils and platelets regularly. - Liver function: assess transaminases and bilirubin before treatment and during therapy. - Cardiac assessment: evaluate ejection fraction in patients with pre‑existing heart disease. - Drug interactions: avoid strong CYP3A4 inhibitors and adjust doses if necessary. - Pregnancy and lactation: discuss potential risks; use only if benefits outweigh risks. - Store at room temperature: keep tablets in the original container, protect from moisture and light.

Imatinib may alter the pharmacokinetics of co‑administered medicines and vice versa.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase imatinib exposure. - Concomitant warfarin: enhanced anticoagulant effect, risk of bleeding. - Antacids containing aluminum or magnesium: reduce oral absorption of imatinib.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may lower imatinib plasma levels. - QT‑prolonging agents (e.g., sotalol, quinidine): potential additive cardiac risk.